[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100570437":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":29,"responsibleParty":58,"collaborators":19,"id":60,"slug":19,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":19,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":19,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":50,"whyStopped":19,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Second Affiliated Hospital of Guangzhou Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"SIRT","EXPERIMENTAL","Patients will receive SIRT treatment",[13],"Procedure: SIRT",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"PROCEDURE","The patients will receive 1-2 sessions of SIRT.",[9],null,[21,26],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Mingyue Cai, Dr.","CONTACT","+86-20-34156205","cai020@yeah.net",{"name":27,"role":23,"phone":24,"phoneExt":19,"email":28},"Kangshun Zhu, Dr.","zhksh010@163.com",[30,49],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"The Second Affiliated Hospital of Guangzhou Medical University","NOT_YET_RECRUITING","Guangzhou","Guangdong","510260","China","CN",{"type":39,"coordinates":40},"Point",[41,42],113.25,23.11667,{"lat":42,"lon":41},[45,47],{"name":27,"role":23,"phone":24,"phoneExt":19,"email":46},"zhksh010@126.com",{"name":27,"role":48,"phone":19,"phoneExt":19,"email":19},"PRINCIPAL_INVESTIGATOR",{"facility":31,"status":50,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":51,"geoPoint":53,"contacts":54},"RECRUITING",{"type":39,"coordinates":52},[41,42],{"lat":42,"lon":41},[55,56,57],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},{"name":27,"role":23,"phone":24,"phoneExt":19,"email":28},{"name":27,"role":48,"phone":19,"phoneExt":19,"email":19},{"type":59,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100570437",false,"NCT06707233","Y-90 SIRT for Unresectable HCC Larger Than 7cm","Y-90 Selective Internal Radiation Therapy for Unresectable Hepatocellular Carcinoma Larger Than 7cm: a Prospective, Single Arm Trial","Inclusion Criteria:\n\n* Pathologically confirmed or clinically diagnosed HCC\n* Unresectable HCC as assessed by a team of surgeons\n* The largest tumor size \\> 7 cm\n* Tumor recurrence after curative treatment (hepatectomy or ablation) is eligible for enrollment\n* At least one measurable intrahepatic target lesion\n* Appropriate for SIRT treatment after evaluation (including SPECT\u002FCT evaluation after arterial perfusion with 99Tc-MAA)\n* Child-Pugh score ≤ 7\n* ECOG PS ≤ 1\n* Adequate organ and hematologic function with platelet count ≥75×10\\^9\u002FL, leukocyte \\>3.0×10\\^9\u002FL, Neutrophil count ≥1.5×10\\^9\u002FL, haemoglobin ≥85 g\u002FL, ALT and AST≤5×ULN, creatinine≤1.5×ULN, and prolongation of prothrombin time ≤4 seconds\n* life expectancy of at least 6 months\n\nExclusion Criteria:\n\n* Macrovascular invasion or extrahepatic metastasis\n* Decompensated liver function, including: ascites, bleeding from gastroesophageal varices, and hepatic encephalopathy\n* Organ (heart and kidneys) dysfunction\n* History of other malignancies\n* Uncontrollable infection\n* History of organ or cells transplantation\n* History of HIV\n* Pregnant or lactating patients","ALL","18 Years","75 Years",{"count":70,"type":71},33,"ESTIMATED","INTERVENTIONAL",[74],"PHASE2","This is a phase II clinical study to evaluate the efficacy and safety of SIRT in patients with HCC greater than 7 cm. After enrollment, patients received yttrium-90 selective internal radiation therapy. The primary endpoint of the study is objective reponse rate (ORR) as assessed by mRECIST. Secondary endpoints were: objective response rate (ORR) as assessed by RECIST 1.1, disease control rate (DCR), progression-free survival (PFS), time to response (TTR), duration of response (DOR), overall survival (OS), and safety (incidence and severity of adverse events).",[77],"Hepatocellular Carcinoma Non-Resectable",[79,80,81],"Hepatocellular Carcinoma","yttrium-90","selective internal radiation therapy","2025-01-26",{"date":84,"type":85},"2025-01-28","ACTUAL",{"date":87,"type":85},"2024-12-01",{"date":89,"type":71},"2027-11-30",{"name":5,"class":6},2]